FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
13.0 puan (24s)Health & MedicineOne-Off3ay
KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Evet 98%+13.0pt
Piyasa kalitesi
47 / 100
Düşük kalite24s Hacim
₺27 B
Likidite
₺71,4 B
Düşük likiditeAlış / Satış
91.0% / 99.0%
Spread
8.0 pt
Geniş spreadPiyasa verileri
3 dakika önce güncellendi
17 Haz 26 21:30 UTC1 Oca 27 04:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketKurallar
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Uzlaşma kaynağı:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in.
- It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma.
- In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Açık piyasalar
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Toplam Hacim
- ₺876,3 Mn
- 24s Hacim
- ₺1 Mn
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Toplam Hacim
- ₺91,4 Mn
- 24s Hacim
- ₺291,7 B
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 daha fazla sonuç
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Toplam Hacim
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Toplam Hacim
- ₺51,6 Mn
- 24s Hacim
- ₺85,3 B
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+1.0pt60%
+2 daha fazla sonuç
- Toplam Hacim
- ₺48,6 Mn
- 24s Hacim
- ₺58,5 B
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Sık sorulan sorular
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) için güncel oranlar nedir?
- Kalshi, 8 Eylül 2026 itibarıyla Yes için 98% fiyatlıyor.
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) ne zaman sonuçlanacak?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) için öngörülen sonuçlanma tarihi 1 Ocak 2027.
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.